Ultragenyx Pharmaceutical Inc. develops and commercializes therapies for serious rare and ultra-rare genetic diseases. Company news commonly covers revenue from approved medicines such as Crysvita, Dojolvi, and Mepsevii, financial guidance, and updates to a portfolio of approved therapies and product candidates for diseases with high unmet medical need and clear biology.
Recurring developments include FDA interactions and clinical data for investigational programs such as UX111 for Sanfilippo syndrome type A, GTX-102 for Angelman syndrome, UX016 for GNE myopathy, and AAV gene therapy candidates for rare metabolic disorders. Updates also include healthcare conference participation, employment inducement equity grants under Nasdaq rules, and corporate restructuring or expense-management actions when disclosed.
Ultragenyx Pharmaceutical Inc. reported first quarter total revenue of $109 million with Crysvita® revenue at $83 million and Dojolvi® revenue at $16 million. The company reaffirmed its 2024 total revenue guidance of $500 million to $530 million, with Crysvita revenue between $375 million to $400 million and Dojolvi revenue at $75 million to $80 million. Positive Phase 1/2 data from the GTX-102 Angelman syndrome study was presented, showing significant improvement. The company continues to see revenue growth and has completed enrollment for its Phase 3 program in osteogenesis imperfecta.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2023 Corporate Responsibility Report, emphasizing its commitment to improving equity and access to innovation in rare diseases. The report showcases efforts in drug development, patient support, employee diversity, community impact, environmental sustainability, and governance. Ultragenyx received multiple awards for its corporate responsibility initiatives, including high rankings in the biotech industry and recognition as a top workplace. The company's dedication to rare disease medicine and community welfare is evident in its comprehensive report.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) completed patient enrollment in Phase 3 studies for setrusumab (UX143) in treating osteogenesis imperfecta (OI). The Orbit study included 158 patients aged 5-25, while the Cosmic study enrolled 66 patients aged 2-7. Positive Phase 2 results showcased a 67% reduction in fracture rates and significant improvements in bone mineral density. Setrusumab demonstrated good tolerability with no serious adverse events reported. The company aims to provide a new treatment option for OI patients, enhancing their quality of life by strengthening bones.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.